Psoriatic arthritis (PsA) and axial Spondyloarthritis (axSpA) share some common therapeutic options, namely TNF-inhibitors, anti-IL-17 and JAK-inhibitors. This evidence concerns the gene IL17A and psoriatic arthritis.